February 15, 2012 - Received this last evening
ALS TDI to Test Multiple
Sclerosis Drug in ALS
The MDA-supported ALS Therapy Development Institute (ALS-TDI) plans to launch a phase 2 clinical trial of TDI 132, a compound that modulates the immune system
• The nonprofit biotech ALS Therapy Development Institute plans to launch a phase 2 trial to determine the safety and tolerability of TDI 132 — also known as fingolimod — in ALS.
• Fingolimod (brand name Gilenya) is approved by the U.S. Food and Drug Administration for the treatment of multiple sclerosis. In humans, Gilenya inhibits certain immune system cells from entering the central nervous system, where they can result in damage to motor neurons.
• ALS TDI reports that mice treated with TDI 132 showed positive outcomes on several disease measures.
To learn more, read the full ALS News Online article.
National Director — Outreach Services & ALS Division
World Leader in ALS Research and Services